The philosophy of Polaris Venture Partners can be summed up simply: diversity is good. That's why about a third of the investments Polaris has made from the $80 million fund raised at its founding in 1996 is in the life sciences; two-thirds are in information technology.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
In its Q2 update, Viking reported that Phase III trials of subcutaneous VK2735 are under way, and that it expects Phase II data for an oral formulation before year’s end.